First subject dosed in Cereno Scientifics first-in-human Phase I trial of novel HDAC inhibitor CS014
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the first subject has been dosed in first-in-human, Phase I, trial of novel HDAC inhibitor CS014, being developed as an innovative therapy for thrombosis prevention.“We are delighted to announce that the first subject in the Phase 1 trial of CS014 has been dosed, marking the first step into clinic for this candidate. Cereno Scientific is determinedly progressing from strength to strength, and this latest important milestone of